Hilary J. Skalski

Hilary J. Skalski

Auto-generated profile, based on publicly available information

Hilary J. Skalski

Department of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JRJake J. Reske
Jake J. Reske
MWMike R. Wilson
Mike R. Wilson
JHJeanne Holladay
Jeanne Holladay
RSRebecca A. Siwicki
Rebecca A. Siwicki
HSHilary Skalski
Hilary Skalski
RCRonald Chandler
Ronald Chandler
TP53 and ARID1A are frequently mutated across cancer but rarely in the same primary tumor. Endometrial cancer has the highest TP53-ARID1A mutual exclusivity rate. However, the functional relationship between TP53 and ARID1A mutations in the endometrium has not been elucidated. We used genetically engineered mice and in vivo genomic approaches to discern both unique and overlapping roles of TP53 and ARID1A in the endometrium. TP53 loss with oncogenic PIK3CAH1047R in the endometrial epithelium results in features of endometrial hyperplasia, adenocarcinoma, and intraepithelial carcinoma. Mutant endometrial epithelial cells were transcriptome profiled and compared to control cells and ARID1A/PIK3CA mutant endometrium. In the context of either TP53 or ARID1A loss, PIK3CA mutant endometrium exhibited inflammatory pathway activation, but other gene expression programs differed based on TP53 or ARID1A status, such as epithelial-to-mesenchymal transition. Gene expression patterns observed in the genetic mouse models are reflective of human tumors with each respective genetic alteration. Consistent with TP53-ARID1A mutual exclusivity, the p53 pathway is activated following ARID1A loss in the endometrial epithelium, where ARID1A normally directly represses p53 pathway genes in vivo, including the stress-inducible transcription factor, ATF3. However, co-existing TP53-ARID1A mutations led to invasive adenocarcinoma associated with mutant ARID1A-driven ATF3 induction, reduced apoptosis, TP63+ squamous differentiation and invasion. These data suggest TP53 and ARID1A mutations drive shared and distinct tumorigenic programs in the endometrium and promote invasive endometrial cancer when existing simultaneously. Hence, TP53 and ARID1A mutations may co-occur in a subset of aggressive or metastatic endometrial cancers, with ARID1A loss promoting squamous differentiation and the acquisition of invasive properties.

23 May 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
HSHilary J Skalski
Hilary J Skalski
AAAmelia R Arendt
Amelia R Arendt
SHShannon K Harkins
Shannon K Harkins
MMMadison MacLachlan
Madison MacLachlan
CCCody J M Corbett
Cody J M Corbett
RCRonald Chandler
Ronald Chandler
The obesity epidemic continues to increase, with half of US women predicted to be obese by 2030. Women with obesity are at increased risk for not only cardiovascular and liver disease, but also reproductive disorders. Although mouse models are useful in studying the effects of obesity, there is inconsistency in obesity-induction methods, diet composition, and mouse strains, and studies using female mice are limited. In this study, we sought to compare the effects of a 45% high-fat diet (HFD) versus a 60% HFD on the uterine estrous cycle of nulligravid C57BL/6J mice. For 22 weeks, we placed a total of 20 mice on either a 60% HFD, 45% HFD, or each HFD-matched control diet (CD). Both HFDs produced significant weight gain, with 60% HFD and 45% HFD gaining significant weight after 2 weeks and 15 weeks, respectively. Additionally, both HFDs led to glucose intolerance, fatty liver, and adipocyte hypertrophy. Mice fed 60% HFD displayed hyperphagia in the first 12 weeks of HFD treatment. Moreover, 60% HFD-treated mice had a longer estrous cycle length and an increased percentage of estrus stage samplings compared to CD-treated mice. Estrous cycle stage-controlled 60% HFD-treated mice displayed an increased estrogen-to-progesterone ratio and decreased ovarian corpora lutea compared to CD-treated mice, which may underlie the observed estrous cycle differences. There was no significant difference between diets regarding endometrial morphology or the percent of endometrial CD45+ immune cells. Our results indicate that consideration is needed when selecting a HFD-induced obesity mouse model for research involving female reproductive health.

19 December 2025 in PLOS ONE
Verified
Journal Article
Open access
SHShannon K. Harkins
Shannon K. Harkins
HSHilary J. Skalski
Hilary J. Skalski
ABAbigail Z. Bennett
Abigail Z. Bennett
LPLaura Ann Pavliscak
Laura Ann Pavliscak
NSNakati C. Sany
Nakati C. Sany
RCRonald Chandler
Ronald Chandler
Chromatin remodeling plays an integral part in endometrial homeostasis through its roles in the maintenance of cell identity, epithelial integrity, and prevention of endometrial disease. Chromodomain-helicase-DNA-binding protein 4 (CHD4) is a chromatin remodeling protein and member of the NuRD complex, which predominantly represses transcription. CHD4 is mutated in endometrial carcinoma, with most mutations resulting in loss of function. CHD4 has been identified as a tumor suppressor and regulator of stemness in human endometrial carcinoma cell lines, but little is known about the tissue-specific roles of CHD4 in the endometrial epithelia in vivo. We generated a conditional Chd4 floxed allele and combined it with BAC-Sprr2f-Cre to drive CHD4 loss in the endometrial epithelium. Consistent with previous reports, BAC-Sprr2f-Cre shows variegated expression within the endometrial epithelium and lacks expression in the oviducts, ovaries, and kidneys. Loss of CHD4 was confirmed by immunohistochemistry, and the percentage of endometrial epithelial cells with and without CHD4 was quantified. Compared to the glandular epithelium, the extent of CHD4 loss was higher in the luminal epithelium and unaffected by age. Mice with conditional knockout of Chd4 had normal endometrial histology. A six-month breeding trial was performed to assess the functional effects of endometrial epithelial CHD4 loss on fertility and found no difference in litter size, average litter size per dam, or pup weight between genotypes. These findings demonstrate that Chd4 conditional knockout using BAC-Sprr2f-Cre is not sufficient to alter the structure and function of the endometrial epithelium or drive tumorigenesis. As CHD4 is frequently co-mutated with other cancer driver genes such as TP53 , PIK3CA , and PTEN , future mouse modeling efforts emulating patient mutational profiles might provide insight into the role of CHD4 in endometrial carcinoma.

24 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
HSHilary J. Skalski
Hilary J. Skalski
ABAbigail Z. Bennett
Abigail Z. Bennett
LWLauren E. Wood
Lauren E. Wood
SHShannon K. Harkins
Shannon K. Harkins
AAAmelia R. Arendt
Amelia R. Arendt
RCRonald Chandler
Ronald Chandler
The uterine endometrium is capable of scarless regeneration under coordinated estrogen and progesterone signaling across the menstrual cycle. Obesity suppresses progesterone production, leading to chronic estrogen exposure and increased endometrial hyperplasia (EH) risk. To define how obesity alters endometrial cell states, endometrial tissues from control and EH-predisposed mice fed either a control diet or a high-fat diet (HFD) were analyzed by single-cell RNA sequencing and tissue phenotyping. HFD reprogrammed endometrial stroma towards an inflammatory, pro-fibrotic state, reducing progesterone receptor-network-associated Aldh1a2 + fibroblasts and expanding estrogen receptor–network-associated Gsn⁺ fibroblasts. HFD further impaired macrophage recruitment and promoted hyperplastic epithelial signatures, consistent with increased disease severity in an EH mouse model. Stromal deletion of Estrogen Receptor α established stromal estrogen signaling as a driver of HFD-induced extracellular matrix (ECM) accumulation. Collectively, these findings identify HFD-driven fibroblast reprogramming as a central mechanism linking estrogen dominance to stromal fibrosis, defective immune clearance, and heightened EH susceptibility. We propose that, in response to progesterone, fibroblast-mediated ECM remodeling is vital to normal endometrial homeostasis. Graphical Abstract HFD-induced estrogen dominance disrupts endometrial fibroblast homeostasis to predispose the endometrium to disease: This study demonstrates that HFD drives estrogen-dependent reprogramming of stromal fibroblasts, characterized by inflammation, stromal ECM accumulation and fibrosis, and a post-ovulatory shift from PGR-network-associated Aldh1a2 + Fibroblasts toward increasing ER-network-associated Gsn + Fibroblasts. These fibroblast changes are accompanied by a reduction in endometrial macrophages and a transcriptomic shift of HFD epithelium toward hyperplastic epithelium seen in a mouse model of EH. Figure made with BioRender.